COVID-19 Update: See the latest on our visitor policy here. Learn More
A Phase I Trial of Capecitabine in Combination with Cemiplimab in Patients with Hormone Receptor Positive Metastatic Breast Cancer
This is a single-center, open-label, phase I study to assess the safety and efficacy of the oral chemotherapy capecitabine in combination with cemiplimab in patients with hormone-receptor–positive (HR+) metastatic breast cancer.
- To evaluate the safety and tolerability of capecitabine in combination with cemiplimab and to determine the recommended phase II dose (RP2D) Secondary Objective: 1. To evaluate the objective response rate (ORR) 2. To evaluate the clinical benefit rate (CBR) 3. To evaluate progression-free survival (PFS)
Chemotherapy (NOS); Immunotherapy
Cemiplimab (); REGN2810 (Cemiplimab); Xeloda (capecitabine); capecitabine ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.